Skip to main content

Table 2 Geometric mean level (GML; 95% CI) in milligrams per liter and percentage of patients with protective antibody levels for both 23F and 6B in different treatment groups at vaccination, at 4 to 6 weeks, and at 1

From: Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs

  RA on methotrexate RA on anti-TNF as monotherapy RA on anti-TNF+MTX SpA on anti-TNF as monotherapy SpA on anti-TNF+MTX SpA on NSAID/analgesics
At vaccination       
Patient number (n) 85 79 89 83 83 86
GML (95% CI) for 23F 0.7 (0.5-1.1) 0.6 (0.4-0.8) 0.7 (0.5-0.9) 0.7 (0.5-0.9) 0.8 (0.6-1.2) 0.97 (0.7-1.4)
GML (95% CI) for 6B 2.0 (1.4-2.8) 1.4 (0.9-2.0) 1.5 (1.1-2.9) 1.5 (1.1-2.1) 1.7 (1.1-2.5) 2.9 (2.1-4.0)
4 to 6 weeks of follow-up
GML (95% CI) for 23F 1.9 (1.3-2.6) 1.9 (1.3-2.7) 1.4 (1.1-1.9) 3.1 (2.2-4.5) 2.5 (1.8-3.5) 6.4 (4.5-9.1)
GML (95% CI) for 6B 3.5 (2.5-4.9) 3.6 (2.5-5.3) 2.3 (1.7-3.2) 4.8 (3.3-6.9) 3.0 (22.1-4.4) 9.5 (6.7-13.6)
Percentage of patients with protective antibody levels for both 23F and 6B 67% 58% 52% 78% 65% 84%
1.5-year follow-up
Patient number (n) 57 50 56 47 49 43
GML (95% CI) for 23F 0.6 (0.4-0.8) 0.5 (0.3-0.8) 0.4 (0.3-0.5) 1.0 (0.6-1.6) 0.8 (0.5-1.3) 2.0 (1.3-3.0)
GML (95% CI) for 6B 1.2 (0.7-1.9) 1.0 (0.6-1.7) 0.6 (0.4-1.0) 1.4 (0.9-2.1) 1.0 (0.6-1.6) 2.8 (1.7-4.6)
Percentage of patients with protective antibody levels for both 23F and 6B 40% 32% 20% 60% 49% 70%
1.5-year follow-up/4 to 6 weeks of follow-up
Relative ratio of protective antibody levels 0.61 0.55 0.38 0.77 0.75 0.84